Amplia Therapeutics Limited Stock Today
| INNMF Stock | USD 0.06 0 7.41% |
Performance3 of 100
| Odds Of DistressOver 71
|
Amplia Therapeutics is trading at 0.058 as of the 29th of November 2024. This is a 7.41 percent increase since the beginning of the trading day. The stock's lowest day price was 0.058. Amplia Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Amplia Therapeutics Limited are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. The company has 194.01 M outstanding shares. More on Amplia Therapeutics Limited
Moving against Amplia Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Amplia Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Amplia Therapeutics Limited [INNMF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.13 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amplia Therapeutics's market, we take the total number of its shares issued and multiply it by Amplia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Amplia Therapeutics classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 194.01 M outstanding shares.
Amplia Therapeutics Limited has accumulated about 14.61 M in cash with (4.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Amplia Therapeutics Probability Of Bankruptcy
Ownership AllocationAmplia Therapeutics holds a total of 194.01 Million outstanding shares. Amplia Therapeutics Limited retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amplia Ownership Details
Amplia Therapeutics Risk Profiles
| Mean Deviation | 9.55 | |||
| Semi Deviation | 11.78 | |||
| Standard Deviation | 17.73 | |||
| Variance | 314.4 |
Amplia Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Amplia Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
| All Next | Launch Module |
Amplia Therapeutics Corporate Management
| Hamish George | Chief Officer | Profile | |
| Benjamin Segal | Clinical Consultant | Profile | |
| BSc BSc | MD CEO | Profile | |
| Frank Gelder | Founding Scientist | Profile | |
| James Taylor | Trials Consultant | Profile | |
| TerrieAnne Cock | Head Biology | Profile | |
| Frederick Reno | Toxicology Consultant | Profile |
Other Information on Investing in Amplia Pink Sheet
Amplia Therapeutics financial ratios help investors to determine whether Amplia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amplia with respect to the benefits of owning Amplia Therapeutics security.